We recognize that while clients initially engage with iCardiac due to the company’s highly differentiated technology offerings, they expand their use of iCardiac’s services due to the customer-centric project management culture of the organization
Rochester, NY (PRWEB) March 19, 2013
iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, today announced that the company has expanded its headquarters by over 40% to support the accelerating demand for the company’s best-in-class cardiac safety solutions. The expansion also includes the creation of a global project management center to enhance iCardiac’s ability to support an increasing number of multi-continent Phase II and III studies.
“We recognize that while clients initially engage with iCardiac due to the company’s highly differentiated technology offerings, they expand their use of iCardiac’s services due to the customer-centric project management culture of the organization,” said Mikael Totterman, chief executive officer of iCardiac. “As a result, we are excited to announce the opening of the global project management center to allow us to continue to deliver world-class customer service to our partners and clients.”
iCardiac Technologies serves seven of the world’s 10 largest pharmaceutical companies, as well as numerous medium- and small-sized biotech, pharmaceutical and medical device clients.
iCardiac Technologies is a global cardiac safety company that has commercialized advanced research originating at leading academic institutions and pharmaceutical companies. Its reach is international, working with pharmaceutical and medical device clients all over the world to bring the best results to cardiac safety. For more information visit: http://www.icardiac.com/.